North America Generic Drugs Market

North America Generic Drugs Market Size (2024 to 2032)

The size of the North American generic drugs market is projected to register a CAGR of 6.89% from 2024 to 2032 and be worth USD 158.55 billion by 2032 from USD 93.04 billion in 2024.

Generic drugs have the same dosage, safety, effects, side effects, intended use, risks, and strength as a genuine drug. An example of a generic drug for diabetes is metformin.

They are cost-effective compared to branded drugs. Generic drugs are also known as abbreviated drugs. To sell a generic drug, the manufacturing company must submit an Abbreviated New Drug Application for approval. This market will increase tremendously during the forecast period.The cost-effectiveness of abbreviated drugs has given it a competitive lead over branded drugs in the market. A key driving factor for generic drugs is patent expiry for branded drugs. Patent for Branded drugs with sales of up to USD 135 billion expired in 2015. Nearly USD 150 billion worth of patents for branded drugs will expire by 2023, which will give generic drugs a huge advantage. One more trend that influences market growth is outsourcing. Currently, most doctors in the US are prescribing generic drugs, which will improve even further. As a result, vendors are using outsourcing to reduce their capital which will be an advantage to generic drugs. The only restraint for this market is the rigid rules set up by the FDA for approval of these drugs and the threat of counterfeit drugs.Factors such as increased disposable incomes, the cost-effectiveness of the drugs, and the rising prevalence of chronic diseases are significant factors boosting the North American generic drugs market. In addition, the key drivers of the market are patent expiry and the adoption of thorough evaluations by various regulatory agencies to guarantee optimum standards throughout medication manufacture.

There is a lack of awareness among individuals about generic drugs, which is estimated to restrict the growth rate unleashing its full potential.

They perceive them as duplicate drugs and do not seem to trust their effectiveness. Many doctors and pharmacists prescribe branded medications over generic drugs to patients. High competition between drugs can affect the market growth during the forecast period. Also, the FDA has set up strict rules for the approval of these types of drugs which makes it difficult to enter the market itself. Also, counterfeit drugs of these generic drugs are abundantly found in the market, which restricts North American generic drugs market growth.

This research report on the North American generic drugs market has been segmented and sub-segmented into the following categories

North America Generic Drugs Market - By Type

• Pure Generic Drugs
• Branded Generic Drugs

North America Generic Drugs Market - By Application 

• The Central Nervous System (CNS)
• Cardiovascular
• Dermatology
• Oncology
• Respiratory
• Others

North America Generic Drugs Market - By Country

• The United States
• Canada
• Rest of North America

Geographically, the U.S. generic drugs market had the highest share of the market in the world in 2023.

The generic drugs market in the United States is anticipated to develop rapidly during the forecast period. Generic medicines have seen a significant increase in manufacturing in the United States since they are less expensive than branded pharmaceuticals and do not need considerable research and testing as generic medicines. Thus, it plays a crucial role in the US healthcare sector. In comparison to the previous year, generic prescriptions increased by 2.2%. Apotex is Canada's largest manufacturer; it is owned and managed by itself. There are around 15 generic medication providers, with 13 businesses having production facilities in the nation.

KEY MARKET PLAYERS

A few of the promising companies operating in the North American generic drugs market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.